DIAGNOSTIC_TEST · Unmapped registry intervention
Artificial Intelligence (AI) test
Find medicine records ·
Find other trials using this name
Clinical trial
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
NCT07458425
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DIAGNOSTIC_TEST · Unmapped registry intervention
Research-use-only multimodal AI risk model
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedThe SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
Design: INTERVENTIONAL · Status: RECRUITING · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Lung Cancerverified · MONDO: lung cancer
Interventions
Artificial Intelligence (AI) testDIAGNOSTIC_TEST
Research-use-only multimodal AI risk modelDIAGNOSTIC_TEST
Sponsors & collaborators
University of Illinois at Chicagolead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07458425 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.